Literature DB >> 8844233

Haemodynamic changes in neurogenic pulmonary oedema: effect of dobutamine.

S C Deehan1, I S Grant.   

Abstract

The haemodynamic and gas exchange abnormalities occurring in neurogenic pulmonary oedema (NPO) were examined retrospectively in 20 patients admitted to the Intensive Therapy Unit (ITU) over a 45-month period (February 1992 to November 1995). In 12 patients, where vasoactive therapy with dobutamine was employed, its effect on haemodynamics was examined. Cardiac index (CI median 2.2 l min-1 m-2) and left ventricular stroke work index (LVSWI 20 g.m.m-2) were markedly depressed, while pulmonary artery wedge pressure (PAWP 17 mmHg), mean pulmonary artery pressure (MPAP 30.5 mmHg), systemic vascular resistance index (SVRI 2852 dyne.s.cm-5.m2) and pulmonary vascular resistance index (PVRI 393 dyne.s.cm-5.m2) were substantially elevated above normal values. Mean arterial pressure (MAP 82.5 mmHg) and heart rate (HR 102 bpm) were within normal limits. The poor oxygenation is indicated by a median PaO2/fiO2 ratio of 18.0 kPa. Patients treated with dobutamine showed significant increases in CI and LVSWI and significant falls in SVRI and PAWP at 2 and 6 h after institution of therapy, and there was a significant rise in PaO2/fiO2 ratio to 27.8 kPa at 6 h. NPO was generally associated with severe depression of myocardial function and elevation of pulmonary vascular pressures. This dysfunction was readily reversed by dobutamine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8844233     DOI: 10.1007/bf01709745

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  12 in total

1.  Neurohemodynamics of pulmonary edema. II. The role of sympathetic pathways in the elevation of pulmonary and stemic vascular pressures following the intracisternal injection of fibrin.

Authors:  S J SARNOFF; L C SARNOFF
Journal:  Circulation       Date:  1952-07       Impact factor: 29.690

2.  Cardiopulmonary responses to uniformly elevated CSF pressure.

Authors:  N C Gonzalez; J Overman
Journal:  J Trauma       Date:  1973-08

3.  Increased intracranial pressure and pulmonary edema. 2. The hemodynamic response of dogs and monkeys to increased intracranial pressure.

Authors:  T B Ducker; R L Simmons
Journal:  J Neurosurg       Date:  1968-02       Impact factor: 5.115

4.  Speculations on neurogenic pulmonary edema (NPE).

Authors:  J Theodore; E D Robin
Journal:  Am Rev Respir Dis       Date:  1976-04

5.  Neurogenic pulmonary edema.

Authors:  G L Colice; M A Matthay; E Bass; R A Matthay
Journal:  Am Rev Respir Dis       Date:  1984-11

6.  Cardiac injury associated with neurogenic pulmonary edema following subarachnoid hemorrhage.

Authors:  S A Mayer; M E Fink; S Homma; D Sherman; G LiMandri; L Lennihan; R A Solomon; L M Klebanoff; A Beckford; E C Raps
Journal:  Neurology       Date:  1994-05       Impact factor: 9.910

7.  Analysis of airway fluid protein concentration in neurogenic pulmonary edema.

Authors:  M B Maron
Journal:  J Appl Physiol (1985)       Date:  1987-02

8.  Pulmonary edema following intracranial hemorrhage.

Authors:  R W Carlson; R C Schaeffer; S G Michaels; M H Weil
Journal:  Chest       Date:  1979-06       Impact factor: 9.410

9.  Pathogenesis of neurogenic pulmonary edema.

Authors:  N P Wray; M B Nicotra
Journal:  Am Rev Respir Dis       Date:  1978-10

10.  Left ventricular wall motion abnormalities in patients with subarachnoid hemorrhage: neurogenic stunned myocardium.

Authors:  T Kono; H Morita; T Kuroiwa; H Onaka; H Takatsuka; A Fujiwara
Journal:  J Am Coll Cardiol       Date:  1994-09       Impact factor: 24.094

View more
  12 in total

1.  Severe myocardial depression following intravenous nimodipine for aneurysmal subarachnoid haemorrhage.

Authors:  Kandasamy Subramani; Murad Ghrew
Journal:  Intensive Care Med       Date:  2004-05-28       Impact factor: 17.440

Review 2.  Extracerebral organ dysfunction in the acute stage after aneurysmal subarachnoid hemorrhage.

Authors:  Wouter J Schuiling; Paul J W Dennesen; Gabriël J E Rinkel
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

3.  Neurogenic pulmonary oedema.

Authors:  G W Kerr
Journal:  J Accid Emerg Med       Date:  1998-07

4.  Pulmonary edema and cardiac dysfunction after resection of a fourth ventricle tumor in a toddler: case report.

Authors:  Gregory G Heuer; Robert S Fenning; Melandee Brown; Todd Kilbaugh; Miguel A Guzman; Alexander R Judkins; Lucy Rorke-Adams; Leslie N Sutton; Phillip B Storm
Journal:  Childs Nerv Syst       Date:  2011-09-14       Impact factor: 1.475

5.  Neurogenic pulmonary edema and other mechanisms of impaired oxygenation after aneurysmal subarachnoid hemorrhage.

Authors:  Paul M Vespa; Thomas P Bleck
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 6.  Cardiovascular and pulmonary complications of aneurysmal subarachnoid hemorrhage.

Authors:  Nicolas Bruder; Alejandro Rabinstein
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

7.  Troponin I in predicting cardiac or pulmonary complications and outcome in subarachnoid haemorrhage.

Authors:  W J Schuiling; P J W Dennesen; J Th J Tans; L M Kingma; A Algra; G J E Rinkel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11       Impact factor: 10.154

8.  Pulmonary edema and blood volume after aneurysmal subarachnoid hemorrhage: a prospective observational study.

Authors:  Reinier G Hoff; Gabriel J E Rinkel; Bon H Verweij; Ale Algra; Cor J Kalkman
Journal:  Crit Care       Date:  2010-03-23       Impact factor: 9.097

9.  Neurogenic cardiopulmonary complications associated with spontaneous cerebellar hemorrhage.

Authors:  Yui-Rwei Young; Chien-Chang Lee; Bor-Fuh Sheu; Shy-Shin Chang
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

Review 10.  Advanced monitoring of systemic hemodynamics in critically ill patients with acute brain injury.

Authors:  Fabio Silvio Taccone; Giuseppe Citerio
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.